MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
of marketable debt...
$250,000K
Proceeds from sale of
marketable equity...
$20,413K
Proceeds from sale of
property and equipment
$698K
Net cash provided by
(used in) investing...
$131,623K
Canceled cashflow
$139,488K
Net increase
(decrease) in cash, cash...
$2,094K
Canceled cashflow
$129,529K
Purchases of marketable
debt securities
$139,488K
Share-based compensation
$20,722K
Accounts receivable
-$5,000K
Operating lease
right-of-use and fixed asset...
$4,136K
Prepaid expenses and
other assets
-$2,993K
Depreciation and
amortization
$739K
Operating lease
right-of-use assets and...
$201K
Proceeds from issuance of
common stock, net
$5,390K
Proceeds from issuance of
common stock under...
$304K
Net cash used in
operating activities
-$125,247K
Net cash (used in)
provided by financing...
-$4,282K
Canceled cashflow
$33,791K
Canceled cashflow
$5,694K
Net loss
-$137,060K
Repurchase of common stock
$9,976K
Accounts payable and
accrued liabilities
-$17,316K
Accretion of discounts on
marketable securities, net
$2,763K
Non-cash recognized
mark-to-market of equity...
$1,239K
(gain)/loss on disposal of
equipment
$660K
Back
Back
Cash Flow
source: myfinsight.com
Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. (ZNTL)